SYNGENE logo

Syngene International Limited Stock Price

NSEI:SYNGENE Community·₹262.2b Market Cap
  • 2 Narratives written by author
  • 0 Comments on narratives written by author
  • 7 Fair Values set on narratives written by author

SYNGENE Share Price Performance

₹658.55
-188.65 (-22.27%)
₹550.00
Fair Value
₹658.55
-188.65 (-22.27%)
19.7% overvalued intrinsic discount
₹550.00
Fair Value
Price ₹658.55
AnalystLowTarget ₹550.00
AnalystConsensusTarget ₹722.22

SYNGENE Community Narratives

AnalystLowTarget·
Fair Value ₹550 19.7% overvalued intrinsic discount

Biologics Expansion And Rising Costs Will Constrain Margins And Depress Future Returns

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value ₹715.63 8.0% undervalued intrinsic discount

Dedicated Peptide Lab And Global Facilities Will Unlock Biopharma Potential

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
₹550
19.7% overvalued intrinsic discount
Revenue
11.84% p.a.
Profit Margin
12.27%
Future PE
51.3x
Price in 2028
₹815.93
₹715.63
8.0% undervalued intrinsic discount
Revenue
13.96% p.a.
Profit Margin
12.34%
Future PE
60.65x
Price in 2028
₹1.03k

Trending Discussion

Updated Narratives

SYNGENE logo

Biologics Expansion And Rising Costs Will Constrain Margins And Depress Future Returns

Fair Value: ₹550 19.7% overvalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
SYNGENE logo

Dedicated Peptide Lab And Global Facilities Will Unlock Biopharma Potential

Fair Value: ₹715.63 8.0% undervalued intrinsic discount
5 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet with moderate growth potential.

0 Risks
1 Reward

Syngene International Limited Key Details

₹37.5b

Revenue

₹11.9b

Cost of Revenue

₹25.6b

Gross Profit

₹20.9b

Other Expenses

₹4.7b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
11.76
68.31%
12.50%
2.6%
View Full Analysis

About SYNGENE

Founded
1993
Employees
6533
CEO
Peter James Bains
WebsiteView website
www.syngeneintl.com

Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, in vivo pharmacology, toxicology, and biologicals; and chemical, formulation, analytical, and clinical development services. It provides lead generation, preclinical development, API, and drug product development services; and clinical trial management, pharmacokinetic analysis/bioanalytical studies, biometrics and clinical data management, central lab, regulatory, medical monitoring, pharmacovigilance, and medical writing services. In addition, the company offers chemistry, biology, safety assessment, computational, and data sciences for traditional small molecule therapeutics; biologics; and specialty modalities, such as peptides, oligonucleotides, antibody-drug conjugates, and targeted degradation/stabilization. It serves pharmaceutical, biotechnology, animal health, nutrition, consumer goods, agrochemical, performance and specialty materials, and other companies. The company has collaborations with Bristol-Myers Squibb, Baxter Inc., and Amgen Inc. The company was incorporated in 1993 and is headquartered in Bengaluru, India. Syngene International Limited is a subsidiary of Biocon Limited.